| Cruz, Luis de la |
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) |
|
|
| Recruiting | 4 | 8600 | US | Naltrexone-Bupropion (NB) Combination, Placebo | Currax Pharmaceuticals | Obesity | 01/29 | 07/29 | | |
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid |
|
|
| Completed | 3 | 610 | US | Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP | Chiesi Farmaceutici S.p.A. | Asthma | 06/24 | 06/24 | | |
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma |
|
|
| Recruiting | 3 | 412 | Europe, Canada, US, RoW | Salbutamol HFA-134a, Salbutamol HFA-152a | GlaxoSmithKline | Asthma | 04/25 | 04/25 | | |
TRITON, NCT04320342 / 2020-002389-16: A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD |
|
|
| Active, not recruiting | 3 | 3433 | Europe, Canada, US, RoW | Beclomethasone Dipropionate, BDP, Glycopyrronium Bromide, glycopyrrolate, GB, Formoterol Fumarate, FF | Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A. | COPD, COPD Exacerbation | 01/26 | 01/26 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
| Recruiting | 2/3 | 560 | US | IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo | Incannex Healthcare Ltd | Obstructive Sleep Apnea | 12/26 | 12/26 | | |
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma |
|
|
| Active, not recruiting | 2 | 220 | Europe, US, RoW | Botensilimab, AGEN1181, Balstilimab, AGEN2034 | Agenus Inc. | Advanced Melanoma | 05/28 | 05/28 | | |
NCT05211986: Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. |
|
|
| Completed | 1/2 | 13 | US | IMM01-STEM | Immunis, Inc. | Muscle Atrophy | 08/24 | 11/24 | | |
| Completed | 1/2 | 29 | Europe, US | ANV419, Pembrolizumab, Ipilimumab | Anaveon AG, Anaveon AG | Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma | 08/24 | 08/24 | | |
NCT04759846: Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma |
|
|
| Withdrawn | 1 | 12 | Europe, RoW | Encorafenib + Binimetinib, Braftovi + Mektovi | Pierre Fabre Medicament | BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment | 05/23 | 05/23 | | |
NCT05451212: Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis |
|
|
| Recruiting | 1 | 24 | US | MuSK-CAART | Cabaletta Bio | MuSK Myasthenia Gravis | 10/28 | 10/28 | | |
| Clinic, Alpha Stem Cell |
RESET-Myositis, NCT06154252: an Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy |
|
|
| Recruiting | 1/2 | 24 | Europe, US | CABA-201 following preconditioning with fludarabine and cyclophosphamide | Cabaletta Bio | Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis | 07/28 | 07/28 | | |
NCT03088878: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
|
|
| Completed | 1/2 | 102 | US | Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, UC-961, Imbruvica, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib, Cirmtuzumab (RDR) plus ibrutinib, Cirmtuzumab plus ibrutinib, Ibrutinib alone | Oncternal Therapeutics, Inc, California Institute for Regenerative Medicine (CIRM), University of California, San Diego, Pharmacyclics LLC. | B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma | 09/24 | 09/24 | | |
RESET-MG, NCT06359041: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis |
|
|
| Recruiting | 1/2 | 12 | US | CABA-201 | Cabaletta Bio | Generalized Myasthenia Gravis (gMG) | 09/29 | 09/29 | | |
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy |
|
|
| Recruiting | 1/2 | 40 | US | NRTX-1001, GABA-secreting interneurons, Sham Comparator | Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM) | Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis | 05/25 | 05/26 | | |
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 12 | Europe, US | CABA-201 | Cabaletta Bio | Systemic Lupus Erythematosus, Lupus Nephritis | 12/27 | 12/27 | | |
NCT05451212: Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis |
|
|
| Recruiting | 1 | 24 | US | MuSK-CAART | Cabaletta Bio | MuSK Myasthenia Gravis | 10/28 | 10/28 | | |
NCT05363046: Noninterventional Study Evaluating Parkinson's Disease Diary Use |
|
|
| Active, not recruiting | N/A | 194 | Europe, Canada, US | | BlueRock Therapeutics | Parkinson's Disease | 10/25 | 10/26 | | |
| Habib, Ali A |
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 235 | Europe, Canada, Japan, US, RoW | Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918 | Regeneron Pharmaceuticals | Generalized Myasthenia Gravis | 05/25 | 03/28 | | |
RESET-MG, NCT06359041: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis |
|
|
| Recruiting | 1/2 | 12 | US | CABA-201 | Cabaletta Bio | Generalized Myasthenia Gravis (gMG) | 09/29 | 09/29 | | |
NCT06704269: Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis |
|
|
| Recruiting | 1/2 | 15 | Japan, US | YTB323 | Novartis Pharmaceuticals | Generalized Myasthenia Gravis | 08/29 | 08/29 | | |
NCT06106672: Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis |
|
|
| Recruiting | 1/2 | 54 | US | CNP-106, Placebo | COUR Pharmaceutical Development Company, Inc. | Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG | 06/26 | 08/26 | | |
NCT05451212: Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis |
|
|
| Recruiting | 1 | 24 | US | MuSK-CAART | Cabaletta Bio | MuSK Myasthenia Gravis | 10/28 | 10/28 | | |
| Recruiting | N/A | 650 | US | | University of Chicago, National Institutes of Health (NIH), Massachusetts General Hospital, Washington University School of Medicine, University of California, Irvine, National Institute of Neurological Disorders and Stroke (NINDS) | Amyotrophic Lateral Sclerosis | 06/25 | 12/25 | | |
| Active, not recruiting | N/A | 400 | US | Blood sample | Yale University, National Center for Advancing Translational Sciences (NCATS), National Institute of Neurological Disorders and Stroke (NINDS) | Myasthenia Gravis | 12/26 | 12/26 | | |
| Nistor, Mani |
NCT05451212: Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis |
|
|
| Recruiting | 1 | 24 | US | MuSK-CAART | Cabaletta Bio | MuSK Myasthenia Gravis | 10/28 | 10/28 | | |
